Integrating VMS Treatment Into Comprehensive Women’s Health Management

Author(s):

Ryan Haumschild, PharmD, MS, MBA, CPEL,JoAnn V. Pinkerton, MD, FACOG, MSCP

Key Takeaways

Hormone therapy for VMS requires careful evaluation of risks, especially in women with pre-existing conditions.
Non-hormonal treatments and lifestyle modifications are vital in managing menopause-related symptoms.
Regular monitoring of bone density and cardiovascular health is essential for comprehensive care.
Personalized treatment plans should consider individual risk factors and patient preferences for optimal management.

Panelists discuss how to effectively integrate vasomotor symptom (VMS) treatment into comprehensive health management plans for women, taking into account the significant comorbidities associated with menopause, such as cardiovascular disease and osteoporosis.

EP: 1.Understanding the Burden of Menopausal Vasomotor Symptoms

EP: 2.Barriers to VMS Treatment and Impact on Long-Term Health

EP: 3.Improving Access and Equity in VMS Treatment

Now Viewing

EP: 4.Integrating VMS Treatment Into Comprehensive Women’s Health Management

EP: 5.Advances in Menopause Treatment: A Focus on the Neurokinin Pathway

EP: 6.Fezolinetant in Focus: Key Findings From the SKYLIGHT Trials

EP: 7.Elinzanetant and the OASIS Trials: Quality of Life and Symptom Relief

EP: 8.Safety Profiles of Neurokinin-Targeted Therapies for VMS

Video content above is prompted by the following:

(FIFFICK) Considering the significant comorbidities often associated with menopause, such as cardiovascular disease and osteoporosis, how should VMS treatment be integrated into a broader health management plan for women?